The HIRN Year 3 Annual Executive Summary Report has been published. We welcome you to download a copy and learn more about the goals, accomplishments, and scientific breakthroughs of the Human Islet Research Network.
The Human Pancreas Analysis Program (HPAP) is performing deep phenotyping of the human endocrine pancreas and its interactions with the immune system. The primary goal is to accumulate, analyze and distribute high value T1D datasets to the diabetes research community. Data from specimens in this database are accessible on the HPAP website.
Register for a HPAP database account to gain access to the data. Refer to the instruction guide on how to navigate the website.
For additional information on how to navigate the HPAP website please view the overview poster on the HPAP News and Publications web page.
An update to the HIRN Resource Browser (v2.1) was completed on May 4th. The HIRN Resource Browser is an online tool that investigators can use to search for Bioreagents, Datasets, Documents, and Technologies generated and/or used by HIRN. The catalog currently has 505 resources. The update adds additional curated content, enables exports of data in JSON, RDF/XML, and allows querying of information using a SPARQL endpoint. This change was undertaken to improve the rigor and reproducibility of HIRN data, by utilizing FAIRprinciples to facilitate knowledge transfer and discovery.
The National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK), at the National Institutes of Health (NIH) is seeking an exceptional investigator to serve as the Director, Division of Diabetes, Endocrinology, and Metabolic Diseases (DEM). Interested candidates should submit a CV and cover letter, that addresses a vision and qualifications, to Camila Torrella by June 15, 2018. For more information please view NIH NIDDK Job Opportunitieswebsite or view the job announcement.
NIH Requests for Applications (RFAs)
RFA-RM-18-011: Cutting Edge Informatics Tools for Illuminating the Druggable Genome (U01 Clinical Trial Not Allowed)
The NIH Common Fund intends to commit $2M to fund 5-6 awards in FY 2019
Letter of Intent due: June 9, 2018
Application due: July 9, 2019
Mechanisms Underlying the Contribution of Type 1 Diabetes Disease-associated Variants (R01 Clinical Trial Not Allowed)
NIDDK intends to commit $3.25 million in FY 2019 to fund 4-5 awards